MicroRNA-18b regulates cell cycle progression in papillary thyroid carcinoma by targeting CDK2: an in vitro experimental study.

IF 1.2 4区 医学 Q3 SURGERY
Ju-Yeon Kim, Jae-Myung Kim, Eun Jung Jung, Youngsim Son, Seung-Jin Kwag, Ji-Ho Park, Jin-Kyu Cho, Han-Gil Kim, Dong-Hwan Kim, Sang-Ho Jeong, Chi-Young Jeong, Young-Tae Ju, Young-Joon Lee
{"title":"MicroRNA-18b regulates cell cycle progression in papillary thyroid carcinoma by targeting <i>CDK2</i>: an <i>in vitro</i> experimental study.","authors":"Ju-Yeon Kim, Jae-Myung Kim, Eun Jung Jung, Youngsim Son, Seung-Jin Kwag, Ji-Ho Park, Jin-Kyu Cho, Han-Gil Kim, Dong-Hwan Kim, Sang-Ho Jeong, Chi-Young Jeong, Young-Tae Ju, Young-Joon Lee","doi":"10.4174/astr.2025.108.6.374","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Papillary thyroid carcinoma (PTC) is the most prevalent endocrine malignancy, and the global incidence has been steadily increasing over the years. Although PTC generally exhibits favorable prognosis, a subset of patients experiences aggressive progression and increased mortality. Current prognostic approaches, reliant on clinic-pathological factors, have limitations, underscoring the need for innovative biomarkers. MicroRNAs (miRs) have emerged as promising candidates due to their roles in cellular processes and cancer progression. Among them, the present study investigated the role of miR-18b in PTC, exploring its potential as a prognostic biomarker.</p><p><strong>Methods: </strong>Utilizing PTC cell lines (TPC1, K1), we examined miR-18b expression and its regulatory effects. The present study used web-based tools to predict the target of miR-18b and to investigate the prognostic impact of miR-18b on thyroid cancer.</p><p><strong>Results: </strong>Through a series of cell proliferation, invasion assay, gap closure, and colony formation assays, we identified that miR-18b suppresses PTC aggressiveness. Dual-luciferase assays confirmed that miR-18b directly targeted the 3'-untranslated region of <i>CDK2</i> and suppressed the expression of <i>CDK2</i>. In addition, miR-18b significantly attenuates the interaction between cyclin A or cyclin E with cyclin-dependent kinase 2 according to co-immunoprecipitation assay. Western blotting of cell cycle proteins and flow cytometry revealed miR-18b-induced cell cycle arrest and apoptosis.</p><p><strong>Conclusion: </strong>Our findings underscore miR-18b's potential as a biomarker for predicting the prognosis of PTC and suggest that it functions through direct regulation of <i>CDK2</i>, influencing cell cycle dynamics. This study not only enhances our understanding of miR-18b in thyroid cancer but also highlights its potential in refining prognostic evaluations and therapeutic strategies.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 6","pages":"374-389"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149990/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Surgical Treatment and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4174/astr.2025.108.6.374","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Papillary thyroid carcinoma (PTC) is the most prevalent endocrine malignancy, and the global incidence has been steadily increasing over the years. Although PTC generally exhibits favorable prognosis, a subset of patients experiences aggressive progression and increased mortality. Current prognostic approaches, reliant on clinic-pathological factors, have limitations, underscoring the need for innovative biomarkers. MicroRNAs (miRs) have emerged as promising candidates due to their roles in cellular processes and cancer progression. Among them, the present study investigated the role of miR-18b in PTC, exploring its potential as a prognostic biomarker.

Methods: Utilizing PTC cell lines (TPC1, K1), we examined miR-18b expression and its regulatory effects. The present study used web-based tools to predict the target of miR-18b and to investigate the prognostic impact of miR-18b on thyroid cancer.

Results: Through a series of cell proliferation, invasion assay, gap closure, and colony formation assays, we identified that miR-18b suppresses PTC aggressiveness. Dual-luciferase assays confirmed that miR-18b directly targeted the 3'-untranslated region of CDK2 and suppressed the expression of CDK2. In addition, miR-18b significantly attenuates the interaction between cyclin A or cyclin E with cyclin-dependent kinase 2 according to co-immunoprecipitation assay. Western blotting of cell cycle proteins and flow cytometry revealed miR-18b-induced cell cycle arrest and apoptosis.

Conclusion: Our findings underscore miR-18b's potential as a biomarker for predicting the prognosis of PTC and suggest that it functions through direct regulation of CDK2, influencing cell cycle dynamics. This study not only enhances our understanding of miR-18b in thyroid cancer but also highlights its potential in refining prognostic evaluations and therapeutic strategies.

MicroRNA-18b通过靶向CDK2调控甲状腺乳头状癌细胞周期进展:一项体外实验研究
目的:甲状腺乳头状癌(PTC)是最常见的内分泌恶性肿瘤,近年来全球发病率稳步上升。尽管PTC通常表现出良好的预后,但一小部分患者会经历侵袭性进展和死亡率增加。目前的预后方法依赖于临床病理因素,有局限性,强调需要创新的生物标志物。由于其在细胞过程和癌症进展中的作用,MicroRNAs (miRs)已成为有希望的候选者。其中,本研究探讨了miR-18b在PTC中的作用,探索其作为预后生物标志物的潜力。方法:利用PTC细胞系(TPC1, K1)检测miR-18b的表达及其调控作用。本研究使用基于网络的工具来预测miR-18b的靶标,并研究miR-18b对甲状腺癌的预后影响。结果:通过一系列细胞增殖、侵袭实验、间隙关闭和集落形成实验,我们发现miR-18b抑制PTC的侵袭性。双荧光素酶测定证实,miR-18b直接靶向CDK2的3'-非翻译区,抑制CDK2的表达。此外,根据共免疫沉淀测定,miR-18b显著减弱细胞周期蛋白A或细胞周期蛋白E与细胞周期蛋白依赖性激酶2之间的相互作用。细胞周期蛋白的Western blotting和流式细胞术显示mir -18b诱导的细胞周期阻滞和凋亡。结论:我们的研究结果强调了miR-18b作为预测PTC预后的生物标志物的潜力,并表明它通过直接调节CDK2发挥作用,影响细胞周期动力学。这项研究不仅增强了我们对miR-18b在甲状腺癌中的理解,而且强调了其在改善预后评估和治疗策略方面的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.30
自引率
7.10%
发文量
75
期刊介绍: Manuscripts to the Annals of Surgical Treatment and Research (Ann Surg Treat Res) should be written in English according to the instructions for authors. If the details are not described below, the style should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publications available at International Committee of Medical Journal Editors (ICMJE) website (http://www.icmje.org).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信